<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03956212</url>
  </required_header>
  <id_info>
    <org_study_id>EM Doxy-2017</org_study_id>
    <nct_id>NCT03956212</nct_id>
  </id_info>
  <brief_title>Inflammatory Mediators in Erythema Migrans</brief_title>
  <official_title>Inflammatory Proteins, Gene Polymorphisms, and Transcriptome Profiles in Patients With Erythema Migrans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Centre Ljubljana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Ljubljana School of Medicine, Slovenia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Centre Ljubljana</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to characterize the inflammatory proteins, gene
      polymorphisms, and transcriptome profiles in patients with erythema migrans to gain better
      insight into pathogenesis of early Lyme borreliosis and to define new immune modulators that
      could serve as biomarkers of disease activity.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>inflammatory proteins in erythema migrans patients</measure>
    <time_frame>up to 12 months follow-up</time_frame>
    <description>The inflammatory immune profiles will be assessed using Luminex to measure the expression of cytokines and chemokines representative of innate and adaptive TH1, TH2, TH17, and B cell responses in serum and if available, skin, of patients during active infection and after treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>gene polymorphisms in erythema migrans patients</measure>
    <time_frame>at enrollment</time_frame>
    <description>ImmunoChip single-nucleotide polymorphism array for dense genotyping of rheumtic disease-relevant genomic variants will be used.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Erythema Migrans</condition>
  <arm_group>
    <arm_group_label>erythema migrans patients treated with doxycycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>adult patients with erythema migrans will be treated with oral doxycycline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline 7 days</intervention_name>
    <description>Patient will be treated with doxycycline orally, 100 mg, bid, 7 days</description>
    <arm_group_label>erythema migrans patients treated with doxycycline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline 14 days</intervention_name>
    <description>Patient will be treated with doxycycline orally, 100 mg, bid, 14 days</description>
    <arm_group_label>erythema migrans patients treated with doxycycline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  erythema migrans in patients &gt; 18 years

        Exclusion Criteria:

          -  pregnancy or immunocompromising conditions

          -  taking antibiotic with antiborrelial activity within 10 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daša Stupica, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Centre Ljubljana</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daša Stupica, MD PhD</last_name>
    <phone>+386 31 689324</phone>
    <email>dasa.stupica@kclj.si</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maša Velušček, MD PhD</last_name>
    <phone>+38631332904</phone>
    <email>masa.veluscek@kclj.si</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daša Stupica, MD, PhD</last_name>
      <phone>+386 31 689 324</phone>
      <email>dasa.stupica@kclj.si</email>
    </contact>
    <contact_backup>
      <last_name>Maša Velušček, MD</last_name>
      <phone>+386 1 522 21 10</phone>
      <email>masa.veluscek@kclj.si</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 15, 2019</study_first_submitted>
  <study_first_submitted_qc>May 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2019</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Ljubljana</investigator_affiliation>
    <investigator_full_name>Daša Stupica</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Lyme Borreliosis</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Outcome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erythema Chronicum Migrans</mesh_term>
    <mesh_term>Glossitis, Benign Migratory</mesh_term>
    <mesh_term>Erythema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

